L'intérêt à découvert pour Kezar Life Sciences donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de Kezar Life Sciences. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

Kezar Life Sciences (NASDAQ:KZR) Stock, Rapport sur les intérêts à découvert

Kezar Life Sciences

Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as Zetomipzomib (KZR-616), and KZR-261.

Kezar Life Sciences Inc

Huawei Technologies is reportedly preparing to test its most powerful artificial intelligence processor to date, with hopes of <a href="https://www.benzinga.com/25/03/44356270/huawei-develops-in-house-chips-to-counter-us-sanctions-and-leap-ahead-in-the-tech-war">replacing high-end chips</a> from U.S. giant Nvidia Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), even as U.S. sanctions continue to stifle China&#8217;s semiconductor ambitions.
What Happened: Huawei has begun the testing phase of its new AI chip, the Ascend 910D, which is designed to rival Nvidia's flagship processors, <a href="https://www.wsj.com/tech/chinas-huawei-develops-new-ai-chip-seeking-to-match-nvidia-8166f606?mod=tech_lead_pos1">reported</a> the Wall Street Journal on Sunday, citing people familiar with the matter.
The chip will undergo a series of technical tests, with samples expected to be ready by late May. The Ascend 910D aims to surpass Nvidia's H100 chip, a popular choice for AI training tasks.
This move marks a significant step forward for Huawei's semiconductor division, which has faced substantial challenges due to <a href="http://v/">U.S. sanctions over</a> the past six years.
See Also:&nbsp;<a href="https://benzinga.com/25/04/45003790/mark-cuban-slams-amazon-for-ripping-off-american-sellers-as-tariffs-are-predicted-to-boost-ecommerce-brands-profi" target="_blank" rel="noreferrer noopener">Mark Cuban Slams Amazon For ‘Ripping Off American Sellers' As Trump Tariffs Are Predicted To Boost Ecommerce Brands' Profits</a>
This year, Huawei plans to ship over 800,000 Ascend 910B and 910C chips. Customers include state-run telecoms and companies like ByteDance, the report noted, citing the sources. 
However, Huawei has been struggling to manufacture these chips on a large scale due to <a href="https://www.benzinga.com/25/04/44963176/chinese-tech-firms-led-by-alibaba-hoard-nvidia-ai-chips-amid-us-sanctions">obstacles in its supply chain</a>. The company has been excluded from working with Taiwan Semiconductor Manufacturing Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>).
Its closest alternative, Semiconductor Manufacturing International, is also restricted from acquiring the latest chip-making technology.
Why It&#8217;s Important: Earlier this month, the U.S. government placed Nvidia's H20 chip—its most advanced processor available for sale in China without a license—on a list of semiconductors facing sales restrictions.
Nvidia revealed that this move would lead to a<a href="https://www.benzinga.com/25/04/44830406/nvidia-to-take-55-billion-hit-over-china-chip-export-restrictions-but-top-analyst-dan-ives-says-hes-not-overly-concerned-all-part-of-the-high-game-of-poker"> $5.5 billion financial hit</a>.
On Sunday, Chamath Palihapitiya spoke about how <a href="https://www.benzinga.com/25/04/45030669/chamath-palihapitiya-says-nvidia-is-huaweis-new-target-a-national-champion-that-crushed-tech-giants-with-a-low-end-disruptor-strategy">Huawei has effectively executed</a> a &#8220;low-end disruptor&#8221; strategy. This strategy focuses on creating products that match or exceed the quality of industry leaders, but at a more affordable price.
He highlighted several companies Huawei has already surpassed, including Telefonaktiebolaget LM Ericsson (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ERIC#NASDAQ">ERIC</a>) and Nokia (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOK#NYSE">NOK</a>).
Previously, the SPAC king raised concerns that <a href="https://in.benzinga.com/markets/25/04/44891778/nvidia-not-acting-in-us-interests-says-chamath-palihapitiya-questions-how-alibaba-or-deepseek-are-one-step-ahead">Nvidia may not be prioritizing</a> the best interests of the U.S.
Benzinga Edge Stock Rankings places Nvidia&#8217;s growth score in the 94th percentile. Curious how other chip stocks compare? <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">Click here to discover more</a>.
Read Next:&nbsp;
<ul>
<li><a href="https://benzinga.com/trading-ideas/movers/25/04/45029805/what-caused-sam-altman-founded-world-network-token-to-soar-57-in-a-week" target="_blank" rel="noreferrer noopener">What Caused Sam Altman-Founded World Network Token To Soar 57% in a Week? What Caused Sam Altman-Founded World Network Token To Soar 57% in a Week?</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Equities

News

Markets

Tech

Media

ERIC

MSFT

Nvidia Faces New Challenge As Huawei Tests Powerful Ascend 910D AI Chip Amid US Sanctions, Aiming To Disrupt High-End Market: Report

Global defense budgets reached unprecedented levels in 2024, driven by mounting conflicts and geopolitical strains. A new report from the Stockholm International Peace Research Institute (SIPRI) showcases a sensational increase in military spending across the globe.
What Happened: According <a href="https://www.sipri.org/media/press-release/2025/unprecedented-rise-global-military-expenditure-european-and-middle-east-spending-surges">to</a> SIPRI, military expenditure rose 9.4% to $2.72 trillion. This marks the most drastic annual increase since the Cold War concluded. All regions reported higher defense outlays, with Europe and the Middle East demonstrating particularly speedy growth. 
More than 100 nations enhanced their military budgets, often reallocating funds from other crucial sectors. U.S. military expenditure touched $997 billion, making up 66% of NATO&#8217;s total and 37% of global defense spending.
See Also: <a href="https://www.benzinga.com/news/25/04/44889497/its-offensive-and-just-plain-wrong-trumps-budget-proposal-to-eliminate-head-start-affecting-over-1-million-parents">&#8216;It&#8217;s Offensive And Just Plain Wrong&#8217;—Trump&#8217;s Budget Proposal To Eliminate Head Start, Affecting Over 1 Million Parents</a>
Why It Matters: Europe&#8217;s military expenditure, including Russia, soared 17%, moving past Cold War-era numbers. Russia&#8217;s defense budget alone rose by 38% to an approximate $149 billion, making up 7.1% of its Gross Domestic Product. 
Ukraine, despite major financial difficulties, increased military spending by 2.9% to $64.7 billion, with its defense budget now taking up all available tax revenue.
The report underscores rising concerns about the long-term impact of prioritizing military budgets over social and economic necessities. 
SIPRI warns that the trend could restructure societies for decades to come. In Europe, the ongoing war in Ukraine and ambiguity surrounding U.S. NATO support have prompted increased defense spending.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/25/04/45030778/trump-running-american-economy-like-a-mafia-don-economist-craig-shapiro-draws-parallels-with-russias-president">Trump Running American Economy Like A &#8216;Mafia Don&#8217;: Economist Craig Shapiro Draws Parallels With Russia&#8217;s President</a></li>
</ul>
Image via Shutterstock

Global

Economics

General

Global Defense Budgets Surge To $2.7 Trillion As Europe And Middle East Lead Steepest Increase Since Cold War: Report

Buybacks

MIELY

Mitsubishi Electric Launches Share Buyback Program For 60M Shares Worth Up To JPY 100B

In a recent private event,&nbsp;Donald Trump Jr., son of the U.S. President, voiced his support for enhanced business cooperation with Eastern Europe.
What Happened: Trump Jr. underscored his close connections to the region during his address at the Trump Business Vision 2025 event organized by businessman Zoltán Aczél and Portfolio at Budapest, Hungary. He spotlighted his Czechoslovakian roots and language proficiency owing to his mother late Ivana Trump, and applauded the region&#8217;s dramatic evolution over the past five decades, <a href="https://www.portfolio.hu/en/economy/20250425/donald-trump-jr-we-want-to-do-a-lot-of-good-business-with-our-friendly-allies-757309">reported</a> Portfolio.
As the&nbsp;Executive Vice President of the&nbsp;Trump Organization, Trump Jr. praised Hungary&#8217;s robust political leadership, specifically Prime Minister Viktor Orbán. He expressed belief in the potential for successful collaboration between American and Hungarian businesses.
He is hopeful that the U.S.-Eastern Europe ties would generate a lot of business amid threats facing the U.S., Hungary and the Central and Eastern European region.
&#8220;I understand the threat that looms from so many places and it&#8217;s not the evil boogeyman of Russia, but likely China,&#8221; pointed out the U.S. President&#8217;s son. 
Trump Jr. recognized the necessity to diversify the U.S. economy&#8217;s dependencies, pointing out the high concentration of pharmaceutical production in China and advanced chip technology in Taiwan. He proposed that Eastern Europe, with its committed workforce and lower labor costs, could assume many activities currently outsourced to China.
&#8220;Pulling away from China is the first step, the dependence is too high,&#8221; stated Trump Jr.
SEE ALSO:&nbsp;<a href="https://benzinga.com/general/sports/25/04/45027895/why-shaq-wont-share-his-500-million-fortune-with-his-kids-we-aint-rich-im-rich-im-not-going-to-hand-it-to-you-you-gotta-earn-it" target="_blank" rel="noreferrer noopener">Why Shaq Won't Share His $500 Million Fortune With His Kids: ‘We Ain't Rich. I'm Rich. I'm Not Going to Hand It to You, You Gotta Earn It&#8217; &#8211; Benzinga</a>
Why It Matters: This comes at a time when the U.S. is experiencing strained relations with China. The ongoing trade war with China has led to a significant decrease in U.S. imports <a href="https://www.benzinga.com/25/04/45026616/trumps-trade-war-causes-sharp-decline-in-us-imports-from-china">from the</a> Asian nation, while China&#8217;s Ministry of Commerce has <a href="https://www.benzinga.com/markets/25/04/44973283/china-denies-trumps-trade-talk-assertion-calls-for-abolition-of-unilateral-tariffs-no-factual-basis">denied rumors</a> of ongoing trade discussions with the U.S.
Against this backdrop, analysts suggest there are concerns that China <a href="https://www.benzinga.com/news/global/25/04/44892820/xi-jinping-could-woo-europe-with-a-potential-china-deal-to-undercut-trumps-tariff-strategy-expert-warns">might leverage</a> the strained U.S.-EU relations to its benefit, leading Beijing to shift the majority exports to Europe.
Trump Jr.&#8217;s call for increased cooperation with Eastern Europe could be seen as a strategic move to diversify the U.S.&#8217;s economic dependencies amid these ongoing tensions. Despite not being a member of the Trump administration, Trump Jr. was hopeful about the renewal of the expired double tax treaty between the U.S. and Hungary, citing the strong relationship between his father, Donald Trump and Prime Minister Orbán.
<ul>
<li>READ MORE:&nbsp;<a href="https://benzinga.com/news/25/04/45022796/this-is-not-really-how-i-pictured-my-life-at-30-air-force-vet-says-he-works-retail-for-18-an-hour-and-feels-" target="_blank" rel="noreferrer noopener">&#8216;This Is Not Really How I Pictured My Life At 30&#8217;—Air Force Vet Says He Works Retail For $18 An Hour And &#8216;Feels Like A Loser&#8217;</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Trump Jr. Leans On His Czech Roots To Boost US-Eastern Europe Ties While 'Pulling Away' From China: 'It's Not The Evil Boogeyman Of Russia, But Likely China'

Consolidated Financial Results Revenue: 5,521.7 billion yen (5% increase year-on-year) Operating profit: 391.8 billion yen (19% increase year-on-year) Profit before income taxes: 437.2 billion yen (20% increase year-on-year) Net profit attributable to Mitsubishi Electric Corp. stockholders: 324.0 billion yen (14% increase year-on-year)

Earnings

Mitsubishi Electric's FY25 Revenue ¥5.521T, Up 5% YoY; Net Profit Attributable To Stockholders ¥324B, Up 14% YoY

CRWD

CrowdStrike Redefines Cybersecurity With Autonomous Charlotte AI Agentic Platform

SYNA

Synaptics Expands Veros Lineup With First Wi-Fi 7 SoCs Tailored For High-Performance, Low-Power IoT Applications

Roper Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROP#NASDAQ">ROP</a>) will release earnings results for the first quarter, before the <a href="https://www.benzinga.com/quote/ROP/earnings">opening bell on Monday, April 28.</a>
Analysts expect the Sarasota, Florida-based company to report quarterly earnings at $4.74 per share, up from $4.41 per share in the year-ago period. Roper Technologies projects to report quarterly revenue at $1.88 billion, compared to $1.68 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On March 24, Roper Technologies disclosed a deal to acquire CentralReach from Insight Partners for a net purchase price of around $1.65 billion.
Roper Technologies shares fell 0.4% to close at $557.70 on Friday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/rop/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul>
<li>JP Morgan analyst Stephen Tusa maintained a Neutral rating and cut the price target from $558 to $465 on April 8, 2025. This analyst has an accuracy rate of 66%.</li>
<li>Stifel analyst Brad Reback initiated coverage on the stock with a Buy rating and a price target of $685 on March 27, 2025. This analyst has an accuracy rate of 71%.</li>
<li>Oppenheimer analyst Christopher Glynn maintained an Outperform rating and raised the price target from $630 to $640 on Jan. 31, 2025. This analyst has an accuracy rate of 77%.</li>
<li>Raymond James analyst Brian Gesuale reiterated a Strong Buy rating and increased the price target from $620 to $655 on Jan. 31, 2025. This analyst has an accuracy rate of 74%.</li>
<li>Barclays analyst Julian Mitchell maintained an Underweight rating and cut the price target from $569 to $562 on Jan. 8, 2025. This analyst has an accuracy rate of 72%.</li>
</ul>
Considering buying ROP stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="587" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28031822/image-183-1024x587.png" alt="" class="wp-image-890254" style="width:551px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28031822/image-183-1024x587.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28031822/image-183-300x172.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28031822/image-183-768x440.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28031822/image-183.png 1122w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/04/45007044/wall-streets-most-accurate-analysts-give-their-take-on-3-real-estate-stocks-delivering-high-dividend-yields-5">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Real Estate Stocks Delivering High-Dividend Yields</a> </li>
</ul>
Photo via Shutterstock

Price Target

Pre-Market Outlook

Analyst Ratings

Trading Ideas

Roper Technologies Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

<ul>
<li>TARA-002 demonstrates 100% complete response rate at any time and 67% 12-month landmark complete response rate in BCG-Unresponsive patients</li>
<li>TARA-002 demonstrates 76% complete response rate at any time and 43% 12-month landmark complete response rate in BCG-Naïve patients</li>
<li>Favorable safety and tolerability profile with no Grade 3 or greater treatment-related adverse events</li>
<li>On track to present updated interim data from approximately 25 six-month evaluable BCG-Unresponsive patients by the end of 2025</li>
<li>Company to host conference call and webcast on Monday, April 28, 2025, at 8:30 a.m. ET</li>
</ul>

TARA

Reported Saturday, Protara Therapeutics Shares Interim Results Highlighting Durable Clinical Responses With TARA-002 In High-Risk NMIBC

The authorities initially prioritized vaccination of adults aged 65 and over, especially those with comorbidities. On April 25, the French health authorities decided to suspend the use of IXCHIQ&#xAE; in persons aged 65 years and older pending further investigation. This is a response to an ongoing investigation of three cases of SAEs resulting in hospitalization, including one death, after vaccination with IXCHIQ&#xAE; among people in La Reunion. The three individuals who were hospitalized were over 80 years old and had pre-existing comorbidities3. These SAEs were reported through the pharmacovigilance system set up by the French health authorities, and causality has not been definitively established. The HAS maintains its current recommendation for IXCHIQ&#xAE; for people aged 18 to 64 years old as part of the ongoing vaccination campaign.

VALN

Reported Saturday, Valneva Provides Update On IXCHIQ Chikungunya Vaccine Use Following HAS Recommendation And Safety Investigation

<ul>
<li>Pivotal Phase 3 CREST trial results show a 32% reduction in the risk of disease-related events, including high-grade disease recurrence or progression, with sasanlimab in combination with standard of care (SOC) Bacillus Calmette-Guérin (BCG) regimen compared to SOC alone</li>
<li>Sasanlimab, a subcutaneously administered PD-1 inhibitor, in combination with BCG represents the first potential treatment advancement for BCG-naïve, high-risk non-muscle invasive bladder cancer in more than 30 years</li>
<li>Results have been shared with global health authorities to support potential regulatory filings</li>
</ul>

Reported Saturday, Pfizer's Sasanlimab Combination Therapy Shows Strong Event-Free Survival Gains In High-Risk Non-Muscle Invasive Bladder Cancer

First results from SunRISe-1 (Cohort 4) show strong disease-free survival rates across high-grade papillary tumors, demonstrating the potential for bladder preservation with 94 percent of patients avoiding radical cystectomy
95 percent progression-free survival rate at 9-months signals the promise of TAR-200 in this high-risk patient population

Reported Saturday, Johnson & Johnson's TAR-200 Monotherapy Demonstrates Strong Early Efficacy In BCG-Unresponsive Bladder Cancer, Achieving Over 80% Disease-Free Survival

<ul>
<li>Robust 24-month complete response rate of 42.3% by K-M for cretostimogene monotherapy in BOND-003 Cohort C</li>
<li>58.3% of patients showed durable complete responses by K-M at 24 months</li>
<li>97.3% of all treated patients remained free from progression to MIBC at 24 month</li>
<li>91.6% of responders remained cystectomy-free at 24 month</li>
<li>No Grade 3 or greater treatment-related adverse events or deaths reported</li>
<li>Strong initial Cohort P data reported 90.5% high-grade recurrence-free survival at 3 and 9 months by K-M</li>
<li>Company will host a conference call and webcast at 8 a.m. EDT on Monday, April 28, 2025</li>
</ul>

CGON

Reported Saturday, CG Oncology Reports Durability In BOND-003 Cohort C And Encouraging Early Results In Cohort P For Cretostimogene Grenadenorepvec

A man has become the first non-verbal, as well as only the third person ever, to receive a Neuralink Brain-Chip Interface (BCI) implant.
What Happened: Author Bradford G Smith suffers from ALS or Amyotrophic Lateral Sclerosis, a very rare nervous system disease that severely impacts motor functions. Smith released a video on the social media platform X to share the update on Sunday.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">I am the 3rd person in the world to receive the <a href="https://twitter.com/neuralink?ref_src=twsrc%5Etfw">@Neuralink</a> brain implant. 1st with ALS. 1st Nonverbal. I am typing this with my brain. It is my primary communication. Ask me anything! I will answer at least all verified users! Thank you <a href="https://twitter.com/elonmusk?ref_src=twsrc%5Etfw">@elonmusk</a>! <a href="https://t.co/bxYO3SBfA2">pic.twitter.com/bxYO3SBfA2</a>
&mdash; Bradford G Smith (Brad) (@ALScyborg) <a href="https://twitter.com/ALScyborg/status/1916630186382291242?ref_src=twsrc%5Etfw">April 27, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Smith says that he uses the Neuralink implant to control the cursor on his laptop as well as Grok AI to create a clone of his own voice to speak. The video Smith shared was also edited by the BCI chip.
Why It Matters: The news comes as Elon Musk has touted his Neuralink BCI as technology that will help completely <a href="https://www.benzinga.com/general/biotech/25/04/44892867/elon-musk-says-neuralink-will-help-blind-people-see-again-will-exceed-the-best-human-eyes">blind people see again</a>, the billionaire shared.&nbsp;&nbsp;
Musk also reiterated that robots would <a href="https://www.benzinga.com/25/04/45031447/elon-musk-says-the-best-human-surgeons-have-just-five-years-before-robots-overtake-them-reveals-instance-when-neuralink-had-to-use-a-robot-for-task-impossible-for-a-human">outperform human surgeons</a> in almost 5 years. He said Neuralink "had to use a robot for the brain-computer electrode insertion, as it was impossible for a human to achieve the required speed and precision."
Elsewhere, Neuralink is also eyeing an<a href="https://www.benzinga.com/general/biotech/25/04/44972585/elon-musks-neuralink-eyes-8-5-billion-pre-money-valuation-in-latest-funding-round-report"> $8.5 billion pre-money valuation</a> in its latest round of funding as the company aims to raise over $500 million, in ongoing talks with investors.
Check out more of Benzinga's Future Of Mobility coverage by<a href="https://www.benzinga.com/topic/mobility"> following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/25/03/44358022/paralyzed-man-moves-objects-with-his-mind-thanks-to-elon-musks-brain-chip">Paralyzed Man Moves Objects With His Mind—Thanks To Elon Musk&#8217;s Brain Chip</a></li>
</ul>
Image Via Shutterstock

Biotech

Man Battling ALS Becomes First Non-Verbal Patient To Receive Elon Musk's Neuralink Brain Implant

As AI chatbots like OpenAI's ChatGPT, Anthropic's Claude, and Perplexity reshape how users search for information, brands are adjusting their strategies to maintain visibility in this new search environment, which is increasingly displacing traditional search engines like Alphabet Inc.'s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) Google.
What Happened: In a shift that threatens Google's dominance, brands are adopting new strategies to ensure they remain visible in the results generated by AI chatbots, <a href="https://www.ft.com/content/9cc6cc0b-759f-4b8e-9ed1-9e32ad0fe22f">reported</a> the Financial Times on Sunday.
Instead of clicking through to websites, many users now rely on AI's synthesized responses, which have decreased web traffic by up to 25%, the report noted, citing research from consultancy Bain.
Taking cognizance of this development, companies like Brandtech and Profound have developed tools that monitor how often brands appear in AI-driven responses, providing insights on how businesses can optimize for these models.
See Also: <a href="https://www.benzinga.com/25/04/44982688/alphabet-q1-earnings-preview-google-parent-stock-at-fork-in-the-road-while-antitrust-concerns-remain" target="_blank" rel="noreferrer noopener">Alphabet Q1 Earnings Preview: Google Parent Stock At ‘Fork In The Road,' While Antitrust Concerns Remain</a>
"This is about much more than just getting your website indexed in their results. This is about recognizing large language models as the ultimate influencer," said Jack Smyth, partner at Brandtech.
Brandtech has developed a &#8220;Share of Model&#8221; tool that helps brands analyze their visibility in AI search results and provides recommendations for optimizing website text and images.&nbsp;
Profound, which secured $3.5 million in seed funding in August, led by Khosla Ventures, offers a data analytics platform that enables brands to monitor popular industry queries and assess their standing within AI search results, the report said.
Why It's Important: On Thursday, Alphabet <a href="https://www.benzinga.com/25/04/44995955/alphabet-q1-earnings-highlights-google-search-youtube-cloud-show-robust-momentum">posted first-quarter revenue</a> of $90.23 billion, a 12% rise compared to the same period last year, beating Wall Street's expectation of $89.2 billion. Revenue from Google Search reached $50.7 billion, up from $46.2 billion a year earlier.
&nbsp;The strong performance helped ease investor concerns about rising competition from AI chatbots like Elon Musk's Grok and fears that Google's own Gemini chatbot and AI-generated summaries might be cutting into its traditional ad-driven search traffic, the report said.
Deepwater Asset Management's Gene Munster previously said that Google's existing search format, which blends AI overviews, blue links, and organic results, <a href="https://www.benzinga.com/25/04/44999838/can-google-adapt-like-amazon-or-will-it-face-ebays-fate-gene-munsters-candid-take-on-the-search-giants-path-forward-in-the-age-of-ai">may fall short against newer</a>, more streamlined search experiences offered by models like Grok, ChatGPT, and Claude.
Price Action: In after-hours trading, Alphabet Inc.&#8217;s Class A shares slipped 0.16% to $161.70, while Class C shares dipped 0.1% to $163.68, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro data</a>.
Alphabet holds a growth score of 64.44%, based on Benzinga Edge Stock Rankings. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">Click here to see how it compares to other companies</a> in the sector.
Photo Courtesy: Ascannio On Shutterstock.com
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44986406/if-you-invested-1000-in-google-stock-when-it-acquired-youtube-heres-how-much-youd-have-today" target="_blank" rel="noreferrer noopener">If You Invested $1,000 in Google Stock When It Acquired YouTube, Here's How Much You'd Have Today</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

GOOG

GOOGL

Google Faces Growing Threat As Chatbots Reshape How Users Search For Brands: Are ChatGPT, Claude And Others AI Bots Set To Be The 'Ultimate' Influencers?

Chinese manufacturers are suspending operations and pursuing alternative markets as U.S. tariff increases take effect, creating ripple effects across global supply chains and threatening millions of jobs.
What Happened: Chinese factories are pausing production due to the impact of U.S. tariffs, as <a href="https://www.cnbc.com/2025/04/28/chinese-factories-stop-production-eye-new-markets-as-us-tariffs-hit.html?ref=biztoc.com">reported</a> by CNBC on Monday. The lost orders are affecting jobs and prompting Chinese exporters to explore new sales strategies, such as livestreaming at home.
According to Cameron Johnson, a senior partner at consulting firm Tidalwave Solutions, factories producing toys, sporting goods, and low-cost Dollar Store-type goods are currently the most affected. &#8220;While not large-scale yet, it is happening in the key [export] hubs of Yiwu and Dongguan, and there is concern that it will grow,&#8221; Johnson said. The impact of recent tariff hikes exceeding 100% is &#8220;way bigger&#8221; than the COVID-19 pandemic&#8217;s disruption, says Ash Monga, CEO of Imex Sourcing Services. 
Woodswool, an athleticwear manufacturer near Shanghai, reports all U.S. orders have been canceled, with over half its production once destined for American customers. The company has pivoted to domestic sales through Baidu&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIDU#NASDAQ">BIDU</a>) livestreaming platform, though its new sales channel generates only modest revenue.
See Also: <a href="https://www.benzinga.com/25/04/44999959/how-the-us-china-trade-war-is-unintentionally-boosting-demand-for-intels-older-chips-amid-economic-uncertainty">Intel&#8217;s Older Parts Are In Demand Thanks To US-China Trade War: &#8216;Tariffs Have Everybody Hedging Their Bets,&#8217; Says Executive</a>
Why It Matters: Many companies are diversifying production to India over Southeast Asia, while others are turning from U.S. customers to those in Europe and Latin America. Some companies have already built businesses on other trade routes from China.
For U.S. investors, these developments signal potential disruption in supply chains and pricing. Goldman Sachs has downgraded China&#8217;s Gross Domestic Product growth <a href="https://www.benzinga.com/government/regulations/25/04/44740040/chinas-growth-outlook-dims-as-trumps-125-tariffs-put-millions-of-jobs-at-risk-goldman-warns?utm_source=chatgpt.com">forecasts to 4.0% for 2025 and 3.5% for 2026</a>, below the government&#8217;s 5% target.
The U.S.-China trade war, under President Donald Trump&#8216;s administration, has led to a <a href="https://www.benzinga.com/25/04/45026616/trumps-trade-war-causes-sharp-decline-in-us-imports-from-china">significant decrease in U.S. imports </a>from China. In response, China has started to<a href="https://www.benzinga.com/news/global/25/04/45004954/china-reportedly-begins-exempting-key-us-imports-from-tariffs-including-pharma-and-aerospace-parts"> exempt some U.S. imports</a> from high tariffs, indicating a possible easing of trade tensions.
The iShares China Large-Cap ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FXI#NYSE">FXI</a>), a widely followed U.S.-listed fund that tracks major Chinese companies, has fallen 4.38% since Trump introduced a 34% &#8220;reciprocal&#8221; tariff on Chinese imports.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/25/04/45005825/us-has-tons-of-solutions-to-secure-rare-earth-production-if-china-halts-exports-experts-say-but-warn-of-significant-challenges">US Has &#8216;Tons Of Solutions&#8217; To Secure Rare Earth Production If China Halts Exports, Experts Say, But Warn Of Significant Challenges</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Image Via Shutterstock

BIDU

Trump Tariffs Prompt Suspension Of Chinese Factory Operations And Shift To New Markets

<ul>
<li>Largest multi-center prospective Investigational Device Exemption (IDE) study for multi-port robotic-assisted urologic surgery in the U.S. presented as&nbsp;a late-breaker at the American Urologic Association annual meeting Company confirms Hugo RAS system submission to&nbsp;the U.S. Food and Drug Administration</li>
</ul>

Reported Saturday, Medtronic's Hugo RAS System Achieves 98.5% Surgical Success Rate In Largest U.S. Robotic-Assisted Urology Study

<ul>
<li>One-year clinical trial data for the next-generation, investigational, Sphere-360&#x2122; single-shot PFA catheter show impressive safety, performance, and efficiency results for paroxysmal Afib</li>
<li>Dual-energy (RF/PF), focal Sphere-9&#x2122; catheter demonstrates efficacy for linear ablation in persistent AFib</li>
<li>Medtronic continues legacy of leadership in innovation, showcasing arrhythmia management portfolio at Heart Rhythm Society annual meeting</li>
</ul>

Reported Saturday, Medtronic's Affera Sphere-360 Catheter Demonstrates Safety And Performance Results For Paroxysmal AFib

Apple Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) is reportedly considering a shift of iPhone assembly to India. However, a renowned analyst has expressed skepticism about the potential effectiveness of this move in mitigating the impact of China tariffs.
What Happened: Craig Moffett, a partner and senior managing director at MoffettNathanson, questioned the feasibility of Apple&#8217;s plans on Friday. He argued that the shift to India wouldn&#8217;t significantly reduce costs related to tariffs, though it would help to some extent, as iPhone components would still be manufactured in China, <a href="https://www.cnbc.com/2025/04/26/apple-iphone-assembly-in-india-wont-cushion-china-tariffs-moffett.html">reported</a> CNBC.
&#8220;You have a tremendous menu&nbsp;of problems created by tariffs,&nbsp;and moving to India doesn&#8217;t&nbsp;solve all the problems,&#8221; Moffett told CNBC&#8217;s &#8220;Fast Money&#8221;. &nbsp;"I would question how that's going to work,&#8221; stated the analyst. 
He added that a trade war impacts both the cost of goods and demand and iPhone may face issues on the latter.
Last week, in a note to clients, MoffettNathanson reasoned that India has enough capacity to fulfill up to half of the U.S. demand for iPhones. Moreover, as the parts would still be from China, there remains an uncertainty over whether the iPhones would face Indian or Chinese tariff rates — or possibly an expensive mix of both.
Moffett told CNBC that the backlash against Apple in China, triggered by U.S. tariffs, will negatively impact iPhone sales. "Volumes are really going to the Huaweis and the Vivos and the local competitors in China rather than to Apple,&#8221; stated the analyst. 
Moffett points out that Apple also isn't receiving support from its carriers AT&amp;T (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/T#NYSE">T</a>), Verizon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VZ#NYSE">VZ</a>), and T. Mobile (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMUS#NASDAQ">TMUS</a>) to help soften the impact of tariffs, after they declared that they won&#8217;t be absorbing the additional costs of tariffs on handsets.
Moffett slashed his price target on Apple stock on Apr 21 to $141 from $184 a share.
SEE ALSO:&nbsp;<a href="https://benzinga.com/news/25/04/45029504/elon-musks-ex-wives-missed-out-on-his-billion-dollar-wealth-heres-why" target="_blank" rel="noreferrer noopener">Elon Musk's Ex-Wives Missed Out on His Billion-Dollar Wealth — Here's Why &#8211; Benzinga</a>
Why It Matters: This skepticism on the heels of previous week&#8217;s report that&nbsp;Apple plans to import most of the iPhones&nbsp;it sells in the U.S. <a href="https://www.benzinga.com/25/04/45014074/apple-plans-iphone-shift-from-china-to-india-amid-tariff-pressures-geopolitical-risks">from India</a> by the end of 2026. This would require the company to double its annual iPhone output in India to over 80 million units.
UBS analyst David Vogt <a href="https://www.benzinga.com/25/04/44973883/analysts-slash-aapl-stock-price-target-amid-anticipated-tariffs-supply-chain-concerns-a-lose-lose-choice">lowered his price target&nbsp;</a>for Apple from $236 to $210 in anticipation of widespread tariffs. Vogt noted that Apple seemed to have expedited the shipment of around one million iPhones, leading to a year-over-year rise in iPhone revenue for the March quarter.
That being said, Moffett is not completely bearish on the iPhone maker. "I think quite highly of Apple. My concern about Apple has been the valuation more than the company."
Benzinga&#8217;s Edge Rankings&nbsp;highlight strong momentum and quality rankings for Apple in the 76th and 85th percentiles, respectively. Curious how other stocks stack up?&nbsp;<a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound" target="_blank" rel="noreferrer noopener">Click here</a>&nbsp;to uncover growth and momentum scores for top stocks.
Over the past month, Apple stock declined nearly 4%, as per <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>. 
<ul>
<li>READ MORE:&nbsp;<a href="https://benzinga.com/markets/cryptocurrency/25/04/45017261/bitcoin-mining-costs-jump-to-137000-per-coin-when-accounting-for-non-cash-expenses-coinshares" target="_blank" rel="noreferrer noopener">Bitcoin Mining Costs Jump To $137,000 Per Coin When Accounting For Non-Cash Expenses: CoinShares &#8211; Benzinga</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

AAPL

TMUS

Analyst Casts Doubt On Apple's Reported Move To Shift iPhone Production To India Amid Rising China Tariff Pressures: 'Doesn't Solve All The Problems'

<ul>
<li>KEYNOTE-689 marks the first positive trial in more than two decades for patients with resected locally advanced head and neck squamous cell carcinoma (LA-HNSCC)</li>
<li>Results to be presented at American Association for Cancer Research (AACR) Annual Meeting 2025 during a Plenary Session and included in official meeting press program</li>
</ul>

Reported Sunday, Merck's Phase 3 KEYNOTE-689 Data Shows KEYTRUDA Significantly Improves Event-Free Survival As Perioperative Therapy In Locally Advanced Head And Neck Cancer

Press Releases

Kezar Life Sciences Announces Clinical Hold of Zetomipzomib IND for Treatment of Lupus Nephritis

Kezar Confirms Receipt of Unsolicited, Non-Binding Acquisition Proposal

Kezar Life Sciences Announces Positive IDMC Safety Review of PORTOLA Trial of Zetomipzomib in Patients with Autoimmune Hepatitis and Provides PALIZADE Update

Kezar Board Unanimously Rejects Unsolicited Concentra Proposal and Adopts Limited Duration Stockholder Rights Plan

Kezar Life Sciences Announces 1-for-10 Reverse Stock Split

Glancy Prongay & Murray LLP Announces Investigation of Kezar Life Sciences, Inc. (KZR)

Kezar Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business Update

Kezar Life Sciences to Present at Virtual KOL Event Hosted by William Blair on Zetomipzomib Clinical Development in Autoimmune Hepatitis and Provide a Safety Update from the PALIZADE Trial for Lupus Nephritis on February 27, 2025

Kezar Life Sciences to Present Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis on March 25, 2025

Kezar Life Sciences Announces Positive Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis (AIH) and Reports Fourth Quarter and Year End 2024 Financial Results

Comments

Kezar Life Sciences

Intérêt court

Kezar Life Sciences (NASDAQ:KZR) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL